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Awide variety of mutations in the parkin gene, including exon deletions and duplications, as well as pointmutations,
result in autosomal recessive early-onset parkinsonism. Interestingly, several of these anomalies were found re-
peatedly in unrelated patients and may therefore result from recurrent, de novo mutational events or from founder
effects. In the present study, haplotype analysis, using 10 microsatellite markers covering a 4.7-cM region known
to contain the parkin gene, was performed in 48 families, mostly from European countries, with early-onset
autosomal recessive parkinsonism. The patients carried 14 distinct mutations in the parkin gene, and each mutation
was detected in more than one family. Our results support the hypothesis that exon rearrangements occurred
independently, whereas some point mutations, found in families from different geographic origins, may have been
transmitted by a common founder.
Introduction
Parkinson’s disease (PD) is a frequent neurodegenerative
disorder with a prevalence of ∼2% in persons 165 years
old (Elbaz et al. 1999). The main clinical features are
rigidity, bradykinesia, and tremor, associated with a
good response to levodopa. The disorder is caused by a
massive loss of dopaminergic neurons in the pars com-
pacta of the substantia nigra and is characterized by the
presence of Lewy bodies (cytoplasmic eosinophilic hy-
aline inclusions) (Fearnley and Lees 1991). Genetic risk
factors are probably involved in the pathogenesis of Par-
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kinson’s disease (de Silva et al. 2000), and several fam-
ilies with clearly established monogenic inheritance have
been reported. The majority of such cases are caused by
mutations in the parkin gene, which result in autosomal
recessive early-onset parkinsonism (MIM 600116) (Hat-
tori et al. 1998a, 1998b; Kitada et al. 1998; Leroy et
al. 1998a; Lu¨cking et al. 1998, 2000; Abbas et al. 1999).
The number of patients with mutations in the a-synu-
clein (Polymeropoulos et al. 1997) or ubiquitin carboxy-
terminal hydrolase (UCH)–L1 genes (Leroy et al. 1998b)
is much smaller. The phenotype associated with parkin
gene mutations is variable but is usually characterized
by early-onset parkinsonism and slow disease progres-
sion (Ishikawa and Tsuji 1996; Lu¨cking et al. 2000).
Postmortem examinations reveal massive loss of dopa-
minergic neurons in the substantia nigra pars compacta
and the absence of Lewy bodies, results suggesting that
the pathologic process may differ from that of idiopathic
Parkinson’s disease (Takahashi et al. 1994; Mori et al.
1998; van de Warrenburg, in press). A wide variety of
mutations in the parkin gene have been detected, in-
cluding exon deletions and duplications, as well as point
mutation (Hattori et al. 1998a, 1998b; Kitada et al.
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Figure 1 Recurrent mutations in the parkin gene and localization of the intragenic microsatellites, showing genetic map of the 10
microsatellites studied (A), exon rearrangements (B, top), and point mutations (B, bottom) that were detected more than once. Exon re-
arrangements are represented as bars corresponding to their size and position, and they are divided into deletions (del) and duplications (dup).
The positions of point mutations are indicated by arrows. The ATG of the initiator methionine codon begins at nucleotide 102 of the published
cDNA (Kitada et al. 1998). The number of index patients with the same mutation is indicated in parentheses. The positions of the microsatellites
in the parkin gene are indicated by dotted arrows. Note the difference, arising from recent results of chromosome 6 sequencing, between the
genetic map and physical map.
1998; Leroy et al. 1998a; Lu¨cking et al. 1998, 2000;
Abbas et al. 1999; Klein et al. 2000; Maruyama et al.
2000; Mun˜oz et al. 2000; Yamamura et al. 2000). The
frequency of these mutations in Europe was estimated
at 50% in families with early-onset parkinsonism that
could have been autosomal recessive inheritance and at
18% in patients who had isolated parkinsonism with
onset at age 45 years (Lu¨cking et al. 2000).
Interestingly, several mutations were found repeatedly
in index patients (Hattori et al. 1998a; Lu¨cking et al.
1998, 2000; Abbas et al. 1999). In our series of patients,
the deletion of exon 3 ( ), the Arg275Trp mu-np 11
tation ( ), the c.202-203 delAG mutation ( ),np 8 np 6
and the c.255delA mutation ( ) were found re-np 6
peatedly. They may therefore result from recurrent, de
novo mutational events or from founder effects. Diver-
gent alleles of markers closely linked to the parkin locus
would suggest independent de novo mutations, whereas
conservation of alleles would support the hypothesis of
a founder effect.
In the present study, haplotype analysis was per-
formed with 10 microsatellite markers covering a 4.7-
cM region that contains the parkin gene, which is lo-
calized on chromosome 6q25.2-q27. The subjects were
members of 48 families with early-onset autosomal re-
cessive parkinsonism who carried 14 different muta-
tions of the parkin gene found in more than one family.
Our results support the hypothesis that exon rearrange-
ments occurred independently, whereas there is evidence
of founder effects in some families with point mutations.
Patients and Methods
Patients
Forty-eight families with early-onset parkinsonism
caused by mutations in the parkin gene, including 69
patients and 49 unaffected relatives, were studied. All
but four families (families TRUS and KUZ from Russia,
families EGPD 25-95 and PW from Germany) have been
described elsewhere (Lu¨cking et al. 1998, 2000; Tassin
et al. 1998; Abbas et al. 1999). The families were selected
for parkin analysis according to the following criteria:
(1) symptoms of parkinsonism (akinesia, rigidity, or
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Table 1
Number and Origin of Index Patients with parkin Mutations Detected More than Once
MUTATIONa
NO. OF INDEX PATIENTS b
NO. OF
HAPLOTYPES COUNTRY OF ORIGINc (NO.)Familial Isolated
Del2 4 0 3 It (3), F (1)
Del3 9 2 8 F (3), N(3), UK (1), It (2), Po (1), R (1)
Del3-4 3 1 2 It (2), F (1), G (1)
Del4 4 0 4 F (1), It (1), UK (1), G (1)
Del5 3 0 3 F (1), It (1), V (1)
Del5-6 0 3 2 L (1), Pa (1), UK (1)
Dup3 2 1 2 It (1), Al (1), S (1)
Dup7 2 0 1 Ar (1), N (1)
Lys211Asn 2 0 2 N (2)
c.321-322insGT 2 0 1 F (1), G (1)
Gly430Asp 1 1 1 UK (1), Ir (1)
c.255delA 4 2 5 F (4), S (1), Po (1)
Arg275Trp 4 4 6 F (2), It (2), Ir (1), UK (1), G (1), G/Ir (1)
c.202-203delAG 3 3 4 UK (2), F (1), N (1), It (1), R (1)
a Del p deletion; Dup p duplication.
b Because index patients were counted separately for the various repeated mutations, the total number
( ) is greater than the number of families studied ( ).np 60 np 48
c Al p Algeria; Ar p Argentina; F p France; G p Germany; Ir p Ireland; It p Italy; L p Lebanon; N
p The Netherlands; Pa p Pakistan; Po p Portugal; R p Russia; UK p United Kingdom; V p Vietnam.
Table 2
Genotypes and Haplotypes of Index Patients with an Exon 2
Deletion in the parkin Gene
IT31 (F) IT22 (F) F155 (F) IT67 (F)
Origin Italy Italy France Italy
Consanguinity No No No No
Mutations del2/del2-4 del2/del3 del2/del3 del2/ND
Marker:
D6S1581 7 1 8 3 7 7 [3 7]
D6S959 1 1 2 2 1 2 2 2
D6S1579 2 5 7 2 5 5 2 2
D6S1599 del/del del/1 del/12 [3 13]
D6S305 7 1 3 1 9 7 [1 3]
D6S411 3 4 3 3 4 3 3 3
AFMa155td9 1 3 1 1 2 2 [1 2]
AFMb281wf1 3 3 3 2 3 3 3 3
D6S1550 2 3 4 1 4 4 [2 3]
D6S1035 2 6 5 4 4 3 [4 5]
NOTE.—Reconstructed disease haplotypes bearing the analyzed
mutation are underlined. The marker closest to the mutation is also
underlined. When phase transmission was unknown, genotypes of
the index patients are indicated in brackets. The haplotypes recon-
structed in families with known consanguinity were considered as a
single haplotype for statistical analysis. del p deletion; dup p du-
plication; Fp familial parkinsonism; Ip isolated parkinsonism; ND
p not determined.
tremor), (2) marked improvement resulting from levo-
dopa treatment, (3) age at onset 45 years for at least
one affected sib, and (4) family history compatible with
autosomal recessive inheritance (except family PW). In
13 of the 48 families, only one member was affected
(referred to as isolated cases). These individuals were
selected according to the same clinical criteria but had
no family history of parkinsonism. They carried parkin
gene mutations, on one or both alleles, that were de-
tected at least twice in unrelated index patients (fig. 1B).
The numbers and origins of the patients are summarized
in table 1.
Genotyping
Blood samples were taken, after written informed con-
sent was obtained, from 69 patients and 49 unaffected
relatives, and genomic DNA was extracted using stan-
dard procedures. Genotyping was performed by PCR,
using the primers specified in the Genome Database
(GDB), with the following microsatellite DNA markers:
D6S1581 (1 cM), D6S959 (0.2 cM), D6S1579 (0.3 cM),
D6S305 (0.1 cM), AFMa155td9 (0 cM), AFMb281wf1
(0.1 cM), D6S411 (0 cM), D6S1550 (1.9 cM), D6S1035
(1.1 cM), and D6S1599 (fig. 1A) (genetic distances ac-
cording to the Whitehead Institute for Biomedical Re-
search). The physical positions of markers D6S411,
AFMa155td9, AFMb281wf1, D6S1550, and D6S1599
differ partly from the genetic map and were determined
with the use of clones from the Sanger Center (PAC
292F10 and RP1-45F6). Marker D6S305 was posi-
tioned, on the basis of PCR results, in patients with
various exon deletions (Leroy et al. 1998b; Lu¨cking et
al. 2000). Marker D6S1599 was amplified with the fol-
lowing primers: D6S1599 forward, 5′-GGG TGT GCT
TGG ATT CCT TCA TG-3′, and D6S1599 reverse, 5′-
TAG CAT GTG GAC TGC ATA TCA AC-3′. The prim-
ers were labeled by fluorescence, and PCR products were
analyzed on an ABI 377 automated sequencer with the
GENESCAN 3.1 and GENOTYPER 1.1.1 software pro-
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Table 3
Genotypes and Haplotypes of Index Patients with an Exon 3 Deletion in the parkin Gene
F141 (F) F155 (F) F431 (F) F192 (F) F195 (F) UK57 (F) F711 (F) IT22 (F) KUS (F) JMP10 (I) UK10551 (I)
Origin France France France N N N Portugal Italy Russia Italy UK
Consanguinity Yes No No No No No Yes No No No No
Mutations Del3/
Del3
Del3/
Del2
Del3/
ND
Del3/
Dup7
Del3/
Lys211Asn
Del3/
Del4
Del3/
Del3
Del3/
Del2
Del3
/Del7
Del3/
Del2-3
Del3/
Gly430Asp
Marker:
D6S1581 3 4 7 7 3 7 1 8 8 3 7 7 7 7 3 8 [7 8] [1 7] 3 3
D6S959 1 2 2 1 2 2 2 2 3 5 2 2 1 1 2 2 [1 2] [2 5] [2 3]
D6S1579 2 2 5 5 2 2 5 2 2 2 2 2 2 2 2 7 [2 5] [2 6] [2 5]
D6S1599 2 2 12/del 3 2 2 3 3 2 3 2 2 2 1/del [4 12] 13/del 2 2
D6S305 1 8 7 9 1 4 7 6 7 3 3 7 3 3 1 3 3 3 1 1 [3 7]
D6S411 3 3 3 4 3 5 3 3 3 4 3 3 3 3 3 3 3 3 [2 5] 3 3
AFMa155td9 1 1 2 2 2 2 2 2 2 2 1 2 2 2 1 1 1 1 [1 2] [1 2]
AFMb281wf1 2 2 3 3 3 3 3 3 2 3 2 3 3 3 2 3 3 3 3 3 [2 3]
D6S1550 2 2 4 4 2 4 2 2 2 2 1 2 2 2 1 4 [2 4] [3 4] 2 2
D6S1035 3 3 3 4 3 5 6 4 4 4 5 2 4 4 4 5 [3 5] [3 5] [2 4]
NOTE.—Data are as defined in Note to table 2. N p The Netherlands; UK p United Kingdom.
grams (all from Applied Biosystems). To ensure accurate
sizing of the alleles, a control DNA sample of individual
1347.02, from the Centre d’Etude du Polymorphisme
Humain, was tested for each marker, and allele numbers
were assigned in increasing order from the smallest to
the largest PCR product.
Haplotypes and Linkage Disequilibrium
Haplotypes were constructed manually to include a
minimum number of recombinations. For each muta-
tion, the disease-associated haplotypes (DHs) were com-
pared among families, to detect (1) common parkin hap-
lotypes that would indicate that the families were related
and (2) a common ancestral DH. The haplotypes con-
structed in families with known consanguinity were con-
sidered as a single haplotype for statistical analysis.
The difference in allele distribution between normal
and carrier chromosomes was evaluated by x2 and two-
tailed Fisher’s exact tests, with Yates correction when
appropriate. The most frequent allele on disease-bearing
chromosomes was defined as a single allele, and the oth-
ers were pooled to form a second allele. The presence
of linkage disequilibrium was tested by ,2Dp (x /N)
where N is the total number of DHs and control chro-
mosomes used. A P value !.01 was considered to be
statistically significant. The proportion of carrier chro-
mosomes bearing the original associated allele was cal-
culated with the equation , wheredp (P  P )/(1 P )D N N
PD and PN are the frequencies of carrier and normal
chromosomes, respectively. The control population com-
prised 140 chromosomes from normal, white subjects.
Results
The origins of the 69 patients and 49 relatives from 48
families with early-onset parkinsonism are shown in
table 1. DHs were constructed in the 38 families in which
unaffected relatives were available (tables 2–4).
Exon Rearrangements
Genotypes or haplotypes of patients with deletion of
exon 2, 3, or 4 are shown in tables 2, 3, and 4, respec-
tively. Patients with exon 2 deletions did not share com-
mon haplotypes, and alleles at markers D6S1579 and
D6S305, which flank the deletion, also differed (table
2). Although allele 3 at marker AFMb281wf1 was pres-
ent on 100% of the disease-causing chromosomes, the
association was not statistically significant, because this
allele was present in 80% of the control population.
Interestingly, marker D6S1599, located in intron 2, was
deleted with exon 2 in 3 of 4 families (table 2). This
observation indicated the existence of at least two dis-
tinct breakpoints and supported the hypothesis of in-
dependent mutational events. Haplotypes of the two pa-
tients with deletions of exons 3 and 4, only one of which
was associated with a deletion of marker D6S1599, also
differed (data not shown).
Four of the five haplotypes that segregated with exon
4 deletions were identical at markers AFMa155td9,
AFMb281wf1, and D6S1550 (table 4). However, the
association was not statistically significant, because these
were the most frequent alleles in the control population
(50%, 82%, and 46%, respectively). Furthermore, the
haplotypes for the markers closest to the deletion
(D6S1599 and D6S305) differed, suggesting indepen-
dent recurrent mutations (table 4). However patient
IT05, who was homozygous for an exon 4 deletion and
who had no known consanguinity, was homozygous for
markers D6S1599, D6S305, and D6S411, which flank
the deletion. Although the patient’s parents were not
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Table 4
Genotypes and Haplotypes of Index Patients with an Exon 4
Deletion in the parkin Gene
F29 (F) DE25 (F) UK57 (F) IT05 (F)
Origin France Germany United Kingdom Italy
Consanguinity No No No No
Mutations del4/ND del4/ND del4/del3 del4/del4
Marker:
D6S1581 3 3 8 4 7 7 9 3
D6S959 2 5 6 1 2 2 5 1
D6S1579 2 3 2 3 2 2 2 5
D6S1599 10 3 4 1 2 3 3 3
D6S305 3 5 3 3 7 3 1 1
D6S411 3 3 3 3 3 3 4 4
AFMa155td9 2 1 2 2 2 1 3 2
AFMb281wf1 3 3 3 3 3 2 1 3
D6S1550 2 4 2 3 2 1 2 2
D6S1035 2 5 3 3 2 5 6 2
NOTE.—Data are as defined in Note to table 2.
Table 5
Genotypes and Haplotypes of Index Patients with c.255delA Mutations in the parkin Gene
F171 (F) F744 (F) F96 (F) S70 (I) UK17275 (F) S74 (I)
Origin France France France Spain Portugal France
Consanguinity No No No No Yes No
Mutations c.255delA/Dup6 c.255delA/Del5 c.255delA/c.255delA c.255delA/c.255delA c.255delA/c.255delA c.255delA/Del3-4
Marker:
D6S1581 3 8 3 3 3 3 [3 8] [3 8] [1 7]
D6S959 1 5 2 1 1 2 2 2 [1 6] 2 2
D6S1579 3 6 2 5 7 7 [2 3] [2 3] [2 5]
D6S1599 7 2 7 4 7 9 [7 9] 7 7 [2 7]
D6S305 8 9 6 3 7 1 [3 8] [3 6] 3 3
D6S411 4 3 3 3 4 3 3 3 3 3 [3 4]
AFMa155td9 2 1 2 2 [1 2] 1 1 1 1 2 2
AFMb281wf1 3 3 2 3 3 3 [2 3] 3 3 2 2
D6S1550 4 2 2 4 3 2 [2 4] [1 2] [2 3]
D6S1035 5 4 5 2 3 2 [3 4] [3 4] [3 4]
NOTE.—Data are as defined in Note to table 2.
known to be related, a common founder for the exon 4
deletion on both chromosomes may be suspected.
Eleven index patients had exon 3 deletions, the most
frequent mutation in the parkin gene, but no significant
association was observed between allele markers and the
DHs (table 3). Allele 2 at marker D6S1599, the marker
closest to the mutation, was present on 4 of 10 disease-
bearing chromosomes but was also the most frequent
allele in the control population (43%). Furthermore, pa-
tients F155 and JMP10 carried alleles 12 and 13, re-
spectively, (whose sizes were very different from those
of alleles 2 and 3), which probably arose from indepen-
dent events. Patients F141 and F711 shared alleles 1-2-
2 at markers D6S959, D6S1579, and D6S1599, but this
association was not statistically significant, because these
alleles were very frequent in the control population
(32%, 50%, and 43%, respectively). This is also the
case for patients F431 and UK57, who shared alleles 2-
2-3 for the same markers, and for patient F195, who
had alleles 2-3 for markers D6S1579 and D6S1599. Al-
leles 2-2-3 were present in 57%, 50%, and 24% of the
control population, respectively. Patients F155 and KUS
shared alleles 2-5-12 at markers D6S959, D6S1579, and
D6S1599; however, because the phase transmission for
patient KUS was not known, we do not know whether
these alleles were carried by the chromosome associated
with the mutation. Because alleles 5 and 12 are rare in
the control population (8% and 6%, respectively), these
two patients may share a common haplotype, but no
definite conclusion can be made.
No common haplotype, or even common marker al-
leles, were observed for the other exon deletions (exons
3 and 4, exons 5 and 6, exon 5) or duplications (exon
3 and exon 7) (data not shown).
Point Mutations
Genotypes or haplotypes of patients with the
c.255delA, c.202-203delAG, and Arg275Trp mutations
are shown in tables 5, 6, and 7, respectively. It is possible
that F744 and S70 (alleles 3-2-2-7 at markers D6S1581,
D6S959, D6S1579, and D6S1599) or S70 and UK17275
(alleles 2-7-3-3-1 at markers D6S1579, D6S1599,
D6S305, D6S411, and AFMa155td9) share a common
haplotype for the c.255delA mutation. No definite con-
clusion can be drawn, however, because the phase of
transmission could not be determined for all markers or
patients (table 5). However, genotype analysis revealed
that, in most cases, the mutation segregated with allele
7 of marker D6S1599 (table 5), which is located 24 kb
downstream of exon 2. This allele was not found in the
62 patients who did not carry the c.255delA mutation
(not determined in one patient) (6/6 vs. 0/62; P !
)..0001
Regarding allele frequencies (independent of the trans-
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Table 6
Genotypes and Haplotypes of Index Patients with the c.202-203delAG Mutation in the parkin Gene
IT20 (F) UK86 (F) NL24 (F) TRUZ (F) S749 (I) UK4720 (I)
Origin Italy United Kingdom Netherlands Russia France United Kingdom
Consanguinity No No No No Yes No
Mutations c.202-203delAG/
Lys161Asn
c.202-203delAG/
ND
c.202-203delAG/
Lys211Asn
c.202-203delAG/
ND
c.202-203delAG/
c.202-203delAG
c.202-203delAG/
c.202-203delAG
Marker:
D6S1581 3 3 4 4 3 1 3 3 3 3 3 3
D6S959 [1 2] 6 1 2 5 [1 2] [1 2] [1 2]
D6S1579 [2 5] 3 4 2 2 [6 8] 4 4 3 3
D6S1599 [2 3] 3 2 2 3 [2 4] 2 2 2 2
D6S305 [3 9] 8 8 9 8 [5 6] 3 3 [1 4]
D6S411 3 3 3 1 3 3 3 3 [3 4] 3 3
AFMa155td9 2 2 [1 2] 2 1 2 2 [1 2] [1 2]
AFMb281wf1 3 3 3 3 3 2 3 3 [2 3] [2 3]
D6S1550 2 2 1 4 2 2 2 2 [2 4] 2 2
D6S1035 [3 6] [3 5] 3 4 [2 3] [4 5] [2 5]
NOTE.—Data are as defined in Note to table 2.
mission phase), all index patients, whether homozygous
or heterozygous for the c.202-203delAG mutation in
exon 2, carried allele 2 at marker D6S1599 (table 6),
but about half the patients with other mutations also
carried this allele (6/6 vs. 29/62; ). Furthermore,P 1 .01
in family UK86, allele 2 did not segregate with the c.202-
203delAG mutation (table 6). Patients IT20, NL24, and
TRUZ shared alleles 3-2-3-2 at markers D6S411,
AFMa155td9, AFMb281wf1, and D6S1550, but this
association was not significant because of the high fre-
quency of these alleles in the control population (59%,
50%, 82%, and 46%, respectively). Although it cannot
be proved, IT20 and NL24 may share a common haplo-
type over the entire region.
At marker D6S305, in intron 7, all patients with the
Arg275Trp mutation in exon 7 carried allele 4 (table 7).
This allele was observed in three other patients who did
not carry the Arg275Trp mutation (8/8, vs. 3/61; P !
). Furthermore, a common haplotype was observed.0001
between patients IT15 and IT63, who shared alleles 2-
2-4-3 at markers D6S1579, D6S1599, D6S305, and
D6S411; however, these alleles were the most frequent
alleles in the control population (50%, 43%, and 59%,
for D6S1579, D6S1599, and D6S411, respectively), ex-
cept for allele 4 at marker D6S305, which was observed
in only 9% in the control population. A common haplo-
type was also observed in UK2329 and S96 who shared
alleles 3-1-2 at markers D6S411, AFMa155td9, and
AFMb281wf1, with allele frequencies of 59%, 38%,
and 9%, respectively. Patients IT15, IT63, S92, and
UK4823 may share this haplotype, but the phase trans-
mission was unknown for these markers.
For the other point mutations (Lys211Asn, c.321-322
insGT, and Gly430Asp), no common haplotypes or al-
lelic associations were observed (data not shown).
Linkage Disequilibrium
We observed a strong linkage disequilibrium (LD) of
0.75 between the c.255delA mutation and allele 7 of
marker D6S1599 (table 8). Allele 7 was present on five
of seven independent chromosomes associated with the
mutation, in patients from France, Portugal, and Spain
(table 5, excluding patient S74, in whom the allele can-
not be attributed to the mutation) but was absent from
the control population ( ) (table 8). However,P ! .0001
patient F96 (from France) and patient S70 (from Spain),
both of whom were homozygous for the c.255delA mu-
tation, carry alleles 7 and 9 at marker D6S1599 (table
5). This observation could be explained by the existence
of two distinct founder mutations or by a recombination
between the mutation and marker D6S1599. Alterna-
tively, a mutation in marker D6S1599 could have
changed allele 7 to 9.
At locus D6S1599, allele 2 was present on 4 of 5 of
the chromosomes associated with the c.202-203delAG
mutation for whom the phase transmission was known.
Because allele 2 of marker D6S1599 was also very fre-
quent in the control population (43%), this association
was not statistically significant ( ) (table 8).P 1 .01
At locus D6S305, ( ) was observed betweenLDp 0.24
allele 4 and the Arg275Trp mutation (table 8). Allele 4
of marker D6S305 was present in five of five patients
from France, Germany, and Italy on chromosomes car-
rying the mutation for which the phase transmission was
known (table 7). This association was statistically sig-
nificant since allele 4 was present in only 28% of the
control chromosomes ( ). LD for markerP ! .003
AFMb281wf1 could not be tested, because the phase
transmission was known in only three subjects. How-
ever, the frequency of allele 2 was much higher in the
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Table 7
Genotypes and Haplotypes of Index Patients with the Arg275Trp Mutation
IT15 (F) IT63 (F) UK 2329 (I) S92 (I) S96 (I) UK 4823 (I) PW (F) EGPD 25-95 (F)
Origin Italy Italy Ireland France France United Kingdom Germany Germany/Ireland
Consanguinity No No No No No No No No
Mutation Arg275Trp/
ND
Arg275Trp/
ND
Arg275Trp/
Gly430
Arg275Trp/
del3-6
Arg275Trp/
ND
Arg275Trp/
del5-6
Arg275Trp/
40pbdel3
Arg275Trp/
ND
Marker:
D6S1581 4 8 7 3 3 8 3 3 3 3 3 3 3 3 7 3
D6S959 [1 2] 1 1 2 5 2 1 [1 2] [1 2] ND 1 2
D6S1579 2 5 2 7 2 5 2 2 [2 5] 3 3 2 2 ND
D6S1599 2 2 2 4 10 13 4 4 [3 4] 2 2 ND 3 2
D6S305 4 8 4 3 [4 3] 4 8 [4 5] [4 1] 4 3 4 9
D6S411 3 3 3 3 3 3 3 3 3 3 3 3 2 1 [4 6]
AFMa155td9 [1 2] [1 2] 1 1 [1 2] 1 1 [1 2] 3 2 1 1
AFMb281wf1 [2 3] [2 3] 2 2 [2 3] 2 2 [2 3] 2 2 [2 3]
D6S1550 2 2 2 4 ND 2 2 2 2 ND [3 4] 3 3
D6S1035 7 3 3 5 3 2 4 5 [2 4] [2 5] 5 4 6 4
NOTE.—Data are as defined in Note to table 2.
eight patients with the Arg275Trp mutation compared
with the control population (68% and 9%, respectively)
( ). It is possible that allele 2 is carried by allP ! .0001
the chromosomes carrying the Arg275Trp mutation.
Discussion
To discriminate between single founder effects and in-
dependent recurrent events, DHs in the parkin region
were established for intragenic and tightly flanking
markers in 48 families with repeatedly observed muta-
tions in the parkin gene.
The disease-associated alleles and haplotypes in fam-
ilies with the same exonic rearrangement were discor-
dant in most of the families, even for markers located
close to the rearrangements. Furthermore, genotypes of
marker D6S1599 revealed at least two distinct break-
points for exon 2 deletions in four unrelated families.
These results suggest that these recurrent mutations
originated independently, although we cannot exclude
a very ancient founder effect associated with recombi-
nations or mutations involving tightly linked markers.
The hypothesis of independent recurrent events was re-
cently confirmed by molecular analysis of the break-
points of the parkin gene in patients with some of the
deletions analyzed here (Asakawa et al. 2000). These
deletions were classified into 18 types. However, one
type of exon 4 deletion was commonly found among
six families. This may reflect the case of our patient
IT05, who is homozygous, without known consanguin-
ity, for an exon 4 deletion, as well as for three markers
flanking the deletion. Thus, even if de novo mutations
occur regularly, a given exon deletion that is transmitted
to subsequent generations becomes a new founder for
this deletion.
Unequal inter- or intrachromosomal crossovers that
result from the misalignment of two homologous flank-
ing sequences may account for the existence of deletions
and for duplications of the same regions of the parkin
gene, as has been reported elsewhere in several genes,
such as the steroid sulfatase gene (Yen et al. 1990) or
the a-globin locus (Nicholls et al. 1987). Unequal cross-
overs, which result in duplications and deletions of a
1.5-Mb region of chromosome 17p11.2, give rise, re-
spectively, to Charcot-Marie-Tooth Type 1A (CMT1A)
(Lupski et al. 1991) and hereditary neuropathy with
liability to pressure palsies (HNPP) (Chance et al. 1993).
Excisions of an intrachromatid loop, resulting exclu-
sively in deletions, also occur in this region of 17p11.2
(Kiyosawa et al. 1995; Lopes et al. 1998; Lopes et al.
1999). If both these mechanisms also cause exon re-
arrangements in the parkin gene, this would explain
why deletions appear to be more frequent than dupli-
cations (29 vs. 5 in our series) in the parkin gene.
Transposable elements (TEs), such as Alu elements,
are also involved in recombination. Almost 0.5% of
known genetic disorders result from TE insertions or
TE-mediated recombination (Deragon and Capy 2000;
Deininger and Batzer 1999). TEs are relatively abundant
in the genome (∼1 Alu/6 kb). The density of Alu ele-
ments in the first 130 kb of intron 2 of the parkin gene,
which is involved in the deletion of exons 2 and 3,
reaches 1 Alu/2.5 kb. This may explain the frequency
of deletions of exons 2, 3, and 3–4, duplications of exon
3, and triplication of exon 2.
Unlike the exon rearrangements, point mutations in
the patients studied may be accounted for by a limited
number of founders. Strong linkage disequilibrium was
observed between the c.255delA mutation in exon 2
and allele 7 of marker D6S1599 in intron 2 (table 5)
and between the Arg275Trp mutation in exon 7 and
allele 4 of marker D6S305 in intron 7 (table 7). These
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Table 8
Linkage Disequilibrium for Three-Point Mutations Found Two or More Times in the parkin Gene
Mutation Locus Allele PD
a PN
b x2 P Pcorrected
c Dd dd
c.255delA D6S1599 7 5/7 0/124 73.65 !.0001 !.001 .75 .75
c.202-203delAG D6S1599 2 4/5 53/124 1.40 1.01 1.1 ND ND
Arg275Trp D6S305 4 5/5 39/140 8.71 !.003 !.03 .24 1
a The frequency of carrier chromosomes is calculated by , where N is the numberP p (n /N)D patients
of haplotypes in which the allele segregating with the mutation could be determined.
b The frequency of control chromosomes is calculated by , where N is the numberP p (n /N)N controls
of control chromosomes used.
c P value was corrected by a factor 10 (correction of Bonferroni), because the same control population
was used to test allelic frequencies of the 10 microsatellites.
d ND p not determined.
associations may reflect the transmission of a single an-
cestral mutation or may be caused by recurrent muta-
tions on a predisposing haplotype, as shown in spino-
cerebellar ataxia 7 (Stevanin et al. 1999). Interestingly,
alleles at markers D6S1579 and D6S305, which cover
a 0.3-cM interval that includes D6S1599, were not con-
served in patients with the c.255delA mutation in exon
2. These observations indicate that multiple recombi-
nations and/or mutations have modified the alleles that
segregate with the closely flanking markers, suggesting
that this mutation can be attributed to very ancient
founder effects. The geographic diversity of the patients
carrying the same allele also supports this hypothe-
sis: patients with the c.255delA mutation come from
France, Spain, and Portugal (tables 5–7).
In contrast, the Arg275Trp mutation may be more
recent, because a common ancestral haplotype between
markers D6S1579 and D6S1550 is suspected. Patients
IT15 and IT63 shared a haplotype between markers
D6S1579 and D6S1550 (not proved for markers
AFMa155td9 and AFMb281wf1, because the phase
was not determined). Furthermore, patients UK2329
and S96 (who were from Ireland and France, respec-
tively) and probably patients S92 and UK4823 (who
were from France and the United Kingdom) also shared
part of this haplotype between marker D6S411 and
marker AFMb281wf1. Although these associations
were not statistically significant for the majority of the
markers, associations between the Arg275Trp muta-
tion and the markers D6S305 and AFMb281wf1 were
significant ( ). The ancestral founder haplo-P ! .001
type could thus have been 2-2-4-3-1-2-2 for markers
D6S1579 to D6S1550 before a recombination separated
haplotype 2-2 (marker D6S1579 and D6S1599) from
haplotype 4-3-1-2-2 (markers D6S305 to D6S1550).
Because the suspected ancestral haplotype was observed
in two Italian patients, the mutation may have arisen
in Italy.
Allele 2 of marker D6S1599 was present in the six
index patients with the c.202-203delAG mutation in
exon 2 and on four of the five chromosomes associated
with the mutation. The association was not statistically
significant, because allele 2 is also very frequent in the
control population. Because of the absence of other
known markers in the introns flanking this mutation,
we cannot distinguish between a single founder effect
on a chromosome carrying allele 2 or recurrent muta-
tions on chromosomes that carry this allele by chance.
It is also difficult to draw conclusions concerning the
three other point mutations analyzed in this study
(Lys211Asn, c.321-322insGT and Gly430Asp). No al-
lelic associations were observed. It is difficult, however,
either to demonstrate or to exclude a founder effect
because of (1) the small number of index patients, (2)
the lack of polymorphic markers in flanking introns
(except for mutation c.321-322insGT in exon 3), and
(3) the absence of relatives who, if available, would
enable us to determine the phase of transmission.
The release of sequence data for the parkin region of
chromosome 6, which is expected in the near future,
should allow us to clarify some of the patients in this
study. The sequencing of a contig of BACs that contain
the parkin gene is in progress, and some of the data
are already available. It will therefore be possible to
define new microsatellite markers in each intron of the
parkin gene and to detect ancient founder effects. In
addition, single-nucleotide polymorphism (SNP) data-
banks, which help in the reconstruction of haplotypes,
are also being created. Only one SNP in the parkin gene,
localized in intron 8, has been identified to date. The
known SNPs in the coding region of the parkin gene
(Abbas et al. 1999) were not informative for the present
study.
In conclusion, a wide variety of mutations in the par-
kin gene have been found repeatedly in patients from
many European populations. Interestingly, the majority
of exon rearrangements seem to result from distinct mu-
tational events, whereas at least two point mutations
may have arisen from a small number of founders.
Therefore, the mechanisms underlying these two groups
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of mutations appear to be different. According to this
hypothesis, the frequency of exon rearrangements
would be expected, in the absence of selection, to in-
crease with the passage of time because of new muta-
tional events, whereas the frequency of point mutations
would be expected to remain stable, because new mu-
tations would be rare.
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